AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30748125 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose calcium carbonate (1250 mg)
Number of subjects: 0
Study 30748125 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose magnesium hydroxide/aluminum hydroxide (800 mg each)
Number of subjects: 0
Study 28763003 — intervention group
Group type: EXPERIMENTAL
Intervention: RTD (Ready-to-Drink beverage with caffeine 200 mg, β-alanine 2.1 g, arginine nitrate 1.3 g, niacin 65 mg, folic acid 325 mcg, Vitamin B12 45 mcg)
Number of subjects: 25
Study 28763003 — intervention group
Group type: EXPERIMENTAL
Intervention: RTD (Ready-to-Drink beverage)
Number of subjects: 25
Study 28763003 — intervention group
Group type: COMPARATOR
Intervention: PLA (Placebo beverage with 12 g of dextrose)
Number of subjects: 25
Study 28763003 — intervention group
Group type: COMPARATOR
Intervention: PLA (Placebo beverage)
Number of subjects: 25
Study 26316226 — intervention group
Group type: EXPERIMENTAL
Intervention: Active lesions during at-risk (AR) period
Number of subjects: 69
Study 26316226 — intervention group
Group type: COMPARATOR
Intervention: Active lesions during not-at-risk (not-AR) period
Number of subjects: 69
Study 26316226 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of lesions with AR proportion
Number of subjects: 69
Study 26316226 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of lesions with time from URI onset
Number of subjects: 69
Study 23559265 — intervention group
Group type: EXPERIMENTAL
Intervention: New chronic poststroke pain (10.6% of participants, 1665 participants)
Number of subjects: 15754
Study 23559265 — intervention group
Group type: EXPERIMENTAL
Intervention: Central poststroke pain (2.7%, 431 participants)
Number of subjects: 15754
Study 23559265 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral neuropathic pain (1.5%, 238 participants)
Number of subjects: 15754
Study 23559265 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain from spasticity (1.3%, 208 participants)
Number of subjects: 15754
Study 23559265 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain from shoulder subluxation (0.9%, 136 participants)
Number of subjects: 15754
Study 23559265 — intervention group
Group type: EXPERIMENTAL
Intervention: More than 1 pain subtype (0.6%, 86 participants)
Number of subjects: 15754
Study 21791660 — intervention group
Group type: EXPERIMENTAL
Intervention: AS03(A)-adjuvanted H5N1 vaccine administered on different schedules (21 days, 14 days, 7 days apart, or same day)
Number of subjects: 0
Study 21791660 — intervention group
Group type: EXPERIMENTAL
Intervention: AS03(A)-adjuvanted H5N1 vaccine administered on standard schedule (21 days apart)
Number of subjects: 0
Study 21791660 — intervention group
Group type: EXPERIMENTAL
Intervention: AS03(A)-adjuvanted H5N1 vaccine administered on accelerated schedules (14 days, 7 days apart, or same day)
Number of subjects: 0
Study 19835535 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalised weight measurement card and advice on optimal gestational weight gain; instructed to record weight at 16, 20, 24, 28, 30, 32 and 34 weeks' gestation
Number of subjects: 236
Study 19835535 — intervention group
Group type: COMPARATOR
Intervention: Control group weighed at recruitment, no instructions about regular weight measurement
Number of subjects: 236
Study 19835535 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalised weight measurement card and advice on optimal gestational weight gain; instructed to record weight at 16, 20, 24, 28, 30, 32 and 34 weeks' gestation (overweight but not obese)
Number of subjects: 236
Study 19835535 — intervention group
Group type: COMPARATOR
Intervention: Control group weighed at recruitment, no instructions about regular weight measurement (overweight but not obese)
Number of subjects: 236
Study 17108585 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer Reminder System (CRS) for antibiotics and asthma/COPD prescriptions
Number of subjects: 53
Study 17108585 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer Reminder System (CRS) for cholesterol prescriptions
Number of subjects: 53
Study 17108585 — intervention group
Group type: EXPERIMENTAL
Intervention: User-friendliness of the Computer Reminder System
Number of subjects: 53
Study 15039413 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavior therapy (CBT)
Number of subjects: 102
Study 15039413 — intervention group
Group type: COMPARATOR
Intervention: Medical care as usual
Number of subjects: 102
Study 11369151 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal information with negative framing
Number of subjects: 300
Study 11369151 — intervention group
Group type: COMPARATOR
Intervention: Verbal information with positive framing
Number of subjects: 300
Study 11369151 — intervention group
Group type: COMPARATOR
Intervention: Numerical information
Number of subjects: 300
Study 9720639 — intervention group
Group type: EXPERIMENTAL
Intervention: Tele-marketing
Number of subjects: 161
Study 9720639 — intervention group
Group type: EXPERIMENTAL
Intervention: Training and no support
Number of subjects: 161
Study 9720639 — intervention group
Group type: EXPERIMENTAL
Intervention: Training and minimal support
Number of subjects: 161
Study 9720639 — intervention group
Group type: EXPERIMENTAL
Intervention: Training and maximal support
Number of subjects: 161
Study 9720639 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 161
Study 7917777 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine therapy
Number of subjects: 40
Study 7917777 — intervention group
Group type: COMPARATOR
Intervention: Drug-free controls
Number of subjects: 40
Study 3073525 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg once daily
Number of subjects: 22
Study 3073525 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine 150 mg twice daily
Number of subjects: 22
Study 29753234 — intervention group
Group type: EXPERIMENTAL
Intervention: HZN+S (hazelnuts with skin)
Number of subjects: 60
Study 29753234 — intervention group
Group type: EXPERIMENTAL
Intervention: HZN-S (hazelnuts without skin)
Number of subjects: 60
Study 29753234 — intervention group
Group type: COMPARATOR
Intervention: Control (dietary recommendations only)
Number of subjects: 60
Study 27344436 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein C zymogen
Number of subjects: 27
Study 27344436 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 26276278 — intervention group
Group type: EXPERIMENTAL
Intervention: Shortened systematic review format
Number of subjects: 56
Study 26276278 — intervention group
Group type: COMPARATOR
Intervention: Full-length systematic review format
Number of subjects: 56
Study 23690355 — intervention group
Group type: EXPERIMENTAL
Intervention: Retention Group with Transpalatal Arch (TPA)
Number of subjects: 30
Study 23690355 — intervention group
Group type: COMPARATOR
Intervention: No Retention Group
Number of subjects: 30
Study 20048655 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous interscalene ropivacaine infusion (ropivacaine 0.2% 2 mL/hr with patient‐controlled 5‐mL boluses every hour)
Number of subjects: 61
Study 20048655 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous interscalene ropivacaine infusion
Number of subjects: 61
Study 20048655 — intervention group
Group type: COMPARATOR
Intervention: Single-shot interscalene block (SS)
Number of subjects: 61
Study 18701824 — intervention group
Group type: EXPERIMENTAL
Intervention: Different treatment strategies
Number of subjects: 348
Study 18701824 — intervention group
Group type: EXPERIMENTAL
Intervention: CD14 genotype and concentrations of CRP and neopterin
Number of subjects: 348
Study 18701824 — intervention group
Group type: EXPERIMENTAL
Intervention: CD14-260 TT genotype
Number of subjects: 348
Study 18701824 — intervention group
Group type: EXPERIMENTAL
Intervention: CD14-260 TT genotype for children with 4 or more carious lesions
Number of subjects: 348
Study 16772285 — intervention group
Group type: EXPERIMENTAL
Intervention: Assisted hatching (AH) with pronase 5 IU/ml for 1 min at 37 degrees C
Number of subjects: 125
Study 16772285 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated embryos)
Number of subjects: 125
Study 12361449 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of education and mattress encasement to reduce mite allergen exposure
Number of subjects: 636
Study 12361449 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 636
Study 9681396 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum TNF-alpha levels in advanced cancer patients
Number of subjects: 27
Study 9681396 — intervention group
Group type: COMPARATOR
Intervention: Serum TNF-alpha levels in healthy controls
Number of subjects: 27
Study 8002642 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% tretinoin
Number of subjects: 28
Study 8002642 — intervention group
Group type: COMPARATOR
Intervention: Vehicle cream
Number of subjects: 28
Study 2600262 — intervention group
Group type: EXPERIMENTAL
Intervention: 40% chlorhexidine varnish
Number of subjects: 10
Study 2600262 — intervention group
Group type: COMPARATOR
Intervention: 10% chlorhexidine varnish
Number of subjects: 10
Study 2600262 — intervention group
Group type: COMPARATOR
Intervention: Control group (0% chlorhexidine varnish)
Number of subjects: 10
Study 1096217 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyproheptadine 4 mg three times daily
Number of subjects: 16
Study 1096217 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 31234530 — intervention group
Group type: EXPERIMENTAL
Intervention: Nut consumers
Number of subjects: 12946
Study 31234530 — intervention group
Group type: COMPARATOR
Intervention: Non-nut consumers
Number of subjects: 12946
Study 28264793 — intervention group
Group type: EXPERIMENTAL
Intervention: Online group-based self-tracking
Number of subjects: 111
Study 28264793 — intervention group
Group type: COMPARATOR
Intervention: Individual self-tracking (control group)
Number of subjects: 111
Study 23968654 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-bolus propofol (2 mg/kg) based on corrected body weight (CBW60)
Number of subjects: 38
Study 23968654 — intervention group
Group type: COMPARATOR
Intervention: Single-bolus propofol (2 mg/kg) based on total body weight (TBW)
Number of subjects: 38
Study 21894361 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of life improvement plan
Number of subjects: 123
Study 21894361 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 123
Study 20034314 — intervention group
Group type: EXPERIMENTAL
Intervention: Standing passengers who held hand straps
Number of subjects: 16
Study 20034314 — intervention group
Group type: EXPERIMENTAL
Intervention: Passengers sitting on the centre of the rear seat
Number of subjects: 16
Study 20034314 — intervention group
Group type: EXPERIMENTAL
Intervention: Passengers facing the window and standing transversely
Number of subjects: 16
Study 20034314 — intervention group
Group type: EXPERIMENTAL
Intervention: First sudden stop
Number of subjects: 16
Study 17764003 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular bupivacaine (20 ml of 0.25%)
Number of subjects: 26
Study 17764003 — intervention group
Group type: COMPARATOR
Intervention: Placebo (20 ml of 0.9% NaCl)
Number of subjects: 26
Study 14730317 — intervention group
Group type: EXPERIMENTAL
Intervention: GM soya
Number of subjects: 7
Study 11164126 — intervention group
Group type: EXPERIMENTAL
Intervention: Systolic Blood Pressure (SBP) > or = 150 mm Hg
Number of subjects: 17762
Study 11164126 — intervention group
Group type: COMPARATOR
Intervention: Systolic Blood Pressure (SBP) < 120 mm Hg
Number of subjects: 17762
Study 11164126 — intervention group
Group type: EXPERIMENTAL
Intervention: Diastolic Blood Pressure (DBP) > or = 90 mm Hg
Number of subjects: 17762
Study 11164126 — intervention group
Group type: COMPARATOR
Intervention: Diastolic Blood Pressure (DBP) < 70 mm Hg
Number of subjects: 17762
Study 11164126 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertension
Number of subjects: 17762
Study 11164126 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihypertensive medications
Number of subjects: 17762
Study 9735663 — intervention group
Group type: EXPERIMENTAL
Intervention: HBeAg-positive sera
Number of subjects: 40
Study 9735663 — intervention group
Group type: EXPERIMENTAL
Intervention: HBeAg-negative sera
Number of subjects: 40
Study 9735663 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 40
Study 9735663 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-TP antibodies
Number of subjects: 40
Study 9735663 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-RT antibodies
Number of subjects: 40
Study 9735663 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-RNase H antibodies
Number of subjects: 40
Study 8285197 — intervention group
Group type: EXPERIMENTAL
Intervention: High-efficiency cuprammonium rayon dialyzer
Number of subjects: 0
Study 8285197 — intervention group
Group type: COMPARATOR
Intervention: High-efficiency polysulfone dialyzer
Number of subjects: 0
Study 8285197 — intervention group
Group type: EXPERIMENTAL
Intervention: Amount of dialysis (Kt/V urea)
Number of subjects: 0
Study 2365214 — intervention group
Group type: EXPERIMENTAL
Intervention: SF-ELS
Number of subjects: 157
Study 2365214 — intervention group
Group type: COMPARATOR
Intervention: PEG-ELS
Number of subjects: 157
Study 2365214 — intervention group
Group type: EXPERIMENTAL
Intervention: Both
Number of subjects: 157
Study 1089426 — intervention group
Group type: EXPERIMENTAL
Intervention: QX-572, 8 mg/kg body weight, administered as a slow intravenous infusion over 30 minutes
Number of subjects: 10
Study 1089426 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving saline, administered as a slow intravenous infusion over 30 minutes
Number of subjects: 10
Study 1089426 — intervention group
Group type: EXPERIMENTAL
Intervention: QX-572
Number of subjects: 10
Study 30764635 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferential current treatment for 30 minutes, twice a day for five days postoperatively.
Number of subjects: 113
Study 30764635 — intervention group
Group type: COMPARATOR
Intervention: Sham interferential current treatment (same pads applied without electrical stimulation).
Number of subjects: 113
Study 28539196 — intervention group
Group type: EXPERIMENTAL
Intervention: Informed Health Choices podcast
Number of subjects: 675
Study 28539196 — intervention group
Group type: COMPARATOR
Intervention: Public service announcements (control group)
Number of subjects: 675
Study 26077006 — intervention group
Group type: EXPERIMENTAL
Intervention: Rheohaemapheresis treatment
Number of subjects: 23
Study 24300626 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspen Ceftriaxone (AC)
Number of subjects: 63
Study 24300626 — intervention group
Group type: COMPARATOR
Intervention: Rocephin (ROC)
Number of subjects: 63
Study 21694649 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicergoline (15 mg/d)
Number of subjects: 60
Study 21694649 — intervention group
Group type: COMPARATOR
Intervention: Imidapril (5 mg/d)
Number of subjects: 60
Study 19307792 — intervention group
Group type: EXPERIMENTAL
Intervention: Early corticosteroid withdrawal
Number of subjects: 37
Study 19307792 — intervention group
Group type: COMPARATOR
Intervention: Chronic steroids (Control)
Number of subjects: 37
Study 16696632 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg nicotine gum plus health education (HE)
Number of subjects: 755
Study 16696632 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg nicotine gum plus motivational interviewing (MI)
Number of subjects: 755
Study 16696632 — intervention group
Group type: COMPARATOR
Intervention: Placebo gum plus health education (HE)
Number of subjects: 755
Study 16696632 — intervention group
Group type: COMPARATOR
Intervention: Placebo gum plus motivational interviewing (MI)
Number of subjects: 755
Study 16642605 — intervention group
Group type: EXPERIMENTAL
Intervention: Head point-through-point electroacupuncture and oral administration of madopa
Number of subjects: 76
Study 16642605 — intervention group
Group type: COMPARATOR
Intervention: Oral administration of madopa
Number of subjects: 76
Study 12841373 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep bruxism patients
Number of subjects: 16
Study 12841373 — intervention group
Group type: COMPARATOR
Intervention: Normal subjects
Number of subjects: 16
Study 12841373 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 16
Study 10063814 — intervention group
Group type: EXPERIMENTAL
Intervention: Precooling (PC)
Number of subjects: 6
Study 10063814 — intervention group
Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 6
Study 7554974 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 micrograms misoprostol orally
Number of subjects: 64
Study 7554974 — intervention group
Group type: COMPARATOR
Intervention: 1 mg vaginal gemeprost
Number of subjects: 64
Study 2182615 — intervention group
Group type: EXPERIMENTAL
Intervention: L-tryptophan
Number of subjects: 13
Study 2182615 — intervention group
Group type: EXPERIMENTAL
Intervention: Artificial evening light
Number of subjects: 13
Study 2182615 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 2182615 — intervention group
Group type: EXPERIMENTAL
Intervention: L-tryptophan and artificial evening light
Number of subjects: 13
Study 84706 — intervention group
Group type: EXPERIMENTAL
Intervention: CHOP regimens (cyclophosphamide, adriamycin, vincristine, and prednisone with either low-dose bleomycin or BCG by scarification)
Number of subjects: 443
Study 84706 — intervention group
Group type: COMPARATOR
Intervention: COP regimen (cyclophosphamide, vincristine, and prednisone with low-dose bleomycin)
Number of subjects: 443
Study 84706 — intervention group
Group type: EXPERIMENTAL
Intervention: CHOP regimens
Number of subjects: 443
Study 84706 — intervention group
Group type: COMPARATOR
Intervention: COP regimen
Number of subjects: 443
Study 31515152 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flow oxygen therapy (HFOT)
Number of subjects: 20
Study 31515152 — intervention group
Group type: COMPARATOR
Intervention: Standard oxygen therapy
Number of subjects: 20
Study 28722093 — intervention group
Group type: EXPERIMENTAL
Intervention: Wheat cellulose particles (1 bag, 2 times per day) + Diosmin tablet (2 pills, 2 times per day)
Number of subjects: 60
Study 28722093 — intervention group
Group type: COMPARATOR
Intervention: Diosmin tablet (2 pills, 2 times per day)
Number of subjects: 60
Study 25422075 — intervention group
Group type: EXPERIMENTAL
Intervention: E-learning education programme
Number of subjects: 0
Study 23798635 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggressive parenteral nutrition (APN)
Number of subjects: 34
Study 23798635 — intervention group
Group type: COMPARATOR
Intervention: Standard parenteral nutrition (SPN)
Number of subjects: 34
Study 21563508 — intervention group
Group type: EXPERIMENTAL
Intervention: biomedical therapy (diclofenec, methotrexate, and sulfasalazine)
Number of subjects: 194
Study 19318436 — intervention group
Group type: EXPERIMENTAL
Intervention: Expert Sources (ES)
Number of subjects: 284
Study 19318436 — intervention group
Group type: EXPERIMENTAL
Intervention: Unattributed Risk Information (URI)
Number of subjects: 284
Study 19318436 — intervention group
Group type: COMPARATOR
Intervention: Control Condition (CC)
Number of subjects: 284
Study 17121380 — intervention group
Group type: EXPERIMENTAL
Intervention: Inosine (1-2 g daily, given twice)
Number of subjects: 32
Study 17121380 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment except for relapse period)
Number of subjects: 32
Study 15253256 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-cuffed PTFE graft
Number of subjects: 89
Study 15253256 — intervention group
Group type: COMPARATOR
Intervention: PTFE graft with vein cuff
Number of subjects: 89
Study 10899382 — intervention group
Group type: EXPERIMENTAL
Intervention: Mecamylamine 5 mg
Number of subjects: 7
Study 10899382 — intervention group
Group type: EXPERIMENTAL
Intervention: Mecamylamine 10 mg
Number of subjects: 7
Study 10899382 — intervention group
Group type: EXPERIMENTAL
Intervention: Mecamylamine 20 mg
Number of subjects: 7
Study 10899382 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 9273914 — intervention group
Group type: EXPERIMENTAL
Intervention: Sober behavioral standard (FB reinforcement)
Number of subjects: 12
Study 9273914 — intervention group
Group type: EXPERIMENTAL
Intervention: Intoxicated behavioral standard (FB reinforcement)
Number of subjects: 12
Study 8360128 — intervention group
Group type: EXPERIMENTAL
Intervention: Mupirocin nasal ointment
Number of subjects: 99
Study 8360128 — intervention group
Group type: COMPARATOR
Intervention: Chlorhexidine/neomycin (Naseptin) cream
Number of subjects: 99
Study 8360128 — intervention group
Group type: EXPERIMENTAL
Intervention: Mupirocin nasal ointment following failure with chlorhexidine/neomycin
Number of subjects: 99
Study 3019375 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilazapril 5 mg
Number of subjects: 12
Study 3019375 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilazapril 10 mg
Number of subjects: 12
Study 3019375 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilazapril 20 mg
Number of subjects: 12
Study 3019375 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilazapril (all doses)
Number of subjects: 12
Study 31789531 — intervention group
Group type: EXPERIMENTAL
Intervention: PRISMS (n = 92)
Number of subjects: 184
Study 31789531 — intervention group
Group type: COMPARATOR
Intervention: Control (existing resource with psychoeducation about sexual orientation, n = 92)
Number of subjects: 184
Study 31822285 — intervention group
Group type: EXPERIMENTAL
Intervention: Fried Phenotype (FP)
Number of subjects: 196
Study 31822285 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive Frailty Assessment Instrument (CFAI)
Number of subjects: 196
Study 28667228 — intervention group
Group type: EXPERIMENTAL
Intervention: PATHway (internet‐enabled, sensor‐based home CR platform with individualised heart rate monitored exercise programmes)
Number of subjects: 120
Study 28667228 — intervention group
Group type: EXPERIMENTAL
Intervention: PATHway
Number of subjects: 120
Study 28667228 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 120
Study 26230741 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin 1300 mg/d
Number of subjects: 300
Study 26230741 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin 900 mg/d
Number of subjects: 300
Study 26230741 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 300
Study 26230741 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin 1300 mg/d and 900 mg/d
Number of subjects: 300
Study 24051993 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual reality training using Xbox Kinect and conventional occupational therapy
Number of subjects: 40